A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors
暂无分享,去创建一个
Eleonora Aronica | Ingmar Blumcke | Horst Urbach | Jorge A. Gonzalez-Martinez | J. González-Martínez | H. Urbach | I. Blumcke | E. Aronica | A. Alexopoulos | Andreas Alexopoulos
[1] T. Ochiai,et al. Adult‐onset angiocentric glioma of epithelioid cell‐predominant type of the mesial temporal lobe suggestive of a rare but distinct clinicopathological subset within a spectrum of angiocentric cortical ependymal tumors , 2012, Neuropathology : official journal of the Japanese Society of Neuropathology.
[2] A. Buccoliero,et al. Angiocentric glioma: clinical, morphological, immunohistochemical and molecular features in three pediatric cases. , 2013, Clinical neuropathology.
[3] C. Barba,et al. The medical and surgical treatment of tumoral seizures: Current and future perspectives , 2013, Epilepsia.
[4] C. Mawrin,et al. MAP‐2 immunoexpression in gliomatosis cerebri , 2009, Histopathology.
[5] Arie Perry,et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups , 2011, Acta Neuropathologica.
[6] P. Crino. mTOR: A pathogenic signaling pathway in developmental brain malformations. , 2011, Trends in molecular medicine.
[7] S. Pfister,et al. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma , 2011, International journal of cancer.
[8] Maria Thom,et al. The clinicopathologic spectrum of focal cortical dysplasias: A consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission 1 , 2011, Epilepsia.
[9] Eleonora Aronica,et al. Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment. , 2012, Brain : a journal of neurology.
[10] S. Lhatoo,et al. Tumor‐related epilepsy and epilepsy surgery , 2013, Epilepsia.
[11] E. Avila. Tumor Associated Epilepsy , 2013 .
[12] A. Alayev,et al. mTOR signaling for biological control and cancer , 2013, Journal of cellular physiology.
[13] O. Wiestler,et al. Surgical Pathology of Chronic Epileptic Seizure Disorders , 1993, Brain pathology.
[14] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[15] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[16] A. Majid,et al. The mTOR pathway as a potential target for the development of therapies against neurological disease. , 2007, Drug news & perspectives.
[17] Frank M. Sacks,et al. IDH 1 and IDH 2 Mutations in Gliomas , 2009 .
[18] S. Hong,et al. Is an epilepsy presurgical evaluation necessary for mid‐grade and high‐grade brain tumors presenting with seizures? , 2013, Epilepsia.
[19] D. Schiff,et al. Update on molecular findings, management and outcome in low-grade gliomas , 2010, Nature Reviews Neurology.
[20] Roger E. Taylor,et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Elger,et al. The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies , 1999, Acta Neuropathologica.
[22] P. V. van Rijen,et al. Pi3K‐mTOR Signaling and AMOG Expression in Epilepsy‐associated Glioneuronal Tumors , 2010, Brain pathology.
[23] A. Hoischen,et al. Angiocentric Glioma: Report of Clinico-Pathologic and Genetic Findings in 8 Cases , 2007, The American journal of surgical pathology.
[24] A. Hoischen,et al. Comprehensive Characterization of Genomic Aberrations in Gangliogliomas by CGH, Array‐based CGH and Interphase FISH , 2008, Brain pathology.
[25] B. Scheithauer,et al. Mixed dysembryoplastic neuroepithelial tumor and ganglioglioma , 1998, Acta Neuropathologica.
[26] M. Preusser,et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells , 2013, Acta Neuropathologica.
[27] W T Blume,et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. , 2001, The New England journal of medicine.
[28] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[29] R. Prayson,et al. Angiocentric glioma: a clinicopathologic review of 5 tumors with identification of associated cortical dysplasia. , 2011, Archives of pathology & laboratory medicine.
[30] P. Deb,et al. Expression of CD34 as a novel marker for glioneuronal lesions associated with chronic intractable epilepsy , 2006, Neuropathology and applied neurobiology.
[31] Webster K. Cavenee,et al. Erratum: The 2007 WHO classification of tumours of the central nervous system (Acta Neuropathol (2007) vol. 114 (97-109)) , 2007 .
[32] E. Aronica,et al. Differential Cellular Gene Expression in Ganglioglioma , 2007, Epilepsia.
[33] R. Prayson,et al. Composite ganglioglioma/dysembryoplastic neuroepithelial tumor: a clinicopathologic study of 8 cases. , 2012, Human pathology.
[34] D. Gutmann,et al. BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma , 2013, Acta Neuropathologica.
[35] J. Barnholtz-Sloan,et al. Gene markers in brain tumors: What the epileptologist should know , 2013, Epilepsia.
[36] M. Honavar,et al. Diffuse form of dysembryoplastic neuroepithelial tumour: the histological and immunohistochemical features of a distinct entity showing transition to dysembryoplastic neuroepithelial tumour and ganglioglioma , 2012, Neuropathology and applied neurobiology.
[37] A. von Deimling,et al. Molecular analysis of the TSC1 and TSC2 tumour suppressor genes in sporadic glial and glioneuronal tumours , 2000, Human Genetics.
[38] Kirsten Schmieder,et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.
[39] H. Zentgraf,et al. Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors , 2010, Brain pathology.
[40] Stephan U Schuele,et al. Long‐term monitoring of brain tumors: When is it necessary? , 2013, Epilepsia.
[41] C. Vecht,et al. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management , 2007, The Lancet Neurology.
[42] M. Nöthen,et al. Mutational analysis of TSC1 and TSC2 genes in gangliogliomas , 2001, Neuropathology and applied neurobiology.
[43] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[44] Heather L. Mulder,et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.
[45] D. Ellison,et al. Rapid Diagnosis of Medulloblastoma Molecular Subgroups , 2011, Clinical Cancer Research.
[46] H. Urbach,et al. Evidence for a Clinically Distinct New Subtype of Grade II Astrocytomas in Patients with Long-term Epilepsy , 2004, Neurosurgery.
[47] P. Crino,et al. Focal malformations of cortical development: New vistas for molecular pathogenesis , 2013, Neuroscience.
[48] Andrey Korshunov,et al. Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.
[49] H. Urbach,et al. Molecular Neuropathology of Epilepsy-Associated Glioneuronal Malformations , 2006, Journal of neuropathology and experimental neurology.
[50] D. Figarella-Branger,et al. Dysembryoplastic Neuroepithelial Tumors Share with Pleomorphic Xanthoastrocytomas and Gangliogliomas BRAFV600E Mutation and Expression , 2013, Brain pathology.
[51] Felix Rosenow,et al. Invasive EEG studies in tumor‐related epilepsy: When are they indicated and with what kind of electrodes? , 2013, Epilepsia.
[52] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[53] Honavar,et al. Histological heterogeneity of dysembryoplastic neuroepithelial tumour: identification and differential diagnosis in a series of 74 cases , 1999, Histopathology.
[54] E. Aronica,et al. BRAF V600E Mutation Is Associated with mTOR Signaling Activation in Glioneuronal Tumors , 2013, Brain pathology.
[55] N. Tandon,et al. Resection strategies in tumoral epilepsy: Is a lesionectomy enough? , 2013, Epilepsia.
[56] E. Aronica,et al. Long‐Term Epilepsy‐Associated Tumors , 2012, Brain pathology.
[57] A. Benabid,et al. Surgical pathology of drug-resistant partial epilepsy. A 10-year-experience with a series of 327 consecutive resections. , 2002, Epileptic disorders : international epilepsy journal with videotape.
[58] J. Duncan,et al. MRI in the diagnosis and management of epileptomas , 2013, Epilepsia.
[59] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.
[60] I. Blümcke,et al. Evidence for developmental precursor lesions in epilepsy‐associated glioneuronal tumors , 1999, Microscopy research and technique.
[61] D. Binder,et al. Tumor-associated epilepsy. , 2009, Neurosurgical focus.
[62] L. Rogers. Chemotherapy and immunotherapy of brain tumors: What the epileptologist must know , 2013, Epilepsia.
[63] Christian E Elger,et al. The Spectrum of Long‐term Epilepsy–associated Tumors: Long‐term Seizure and Tumor Outcome and Neurosurgical Aspects , 2003, Epilepsia.
[64] T Pietsch,et al. NeuN: a useful neuronal marker for diagnostic histopathology. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[65] Karsten Wrede,et al. Molecular classification of low-grade diffuse gliomas. , 2010, The American journal of pathology.
[66] A. Becker,et al. Recent aspects of classification and epidemiology of epilepsy‐associated tumors , 2013, Epilepsia.
[67] A. Becker,et al. Tumor recurrence and malignant progression of gangliogliomas , 2008, Cancer.
[68] S. Blackburn,et al. Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature , 2009, Journal of Neuro-Oncology.
[69] B. Scheithauer,et al. Composite pleomorphic xanthoastrocytoma and ganglioglioma: report of four cases and review of the literature. , 1997, The American journal of surgical pathology.
[70] Ingmar Blümcke,et al. Microtubule-associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of low-grade neuroepithelial tumors , 2004, Acta Neuropathologica.
[71] Liliana Goumnerova,et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1 , 2013, Proceedings of the National Academy of Sciences.
[72] F. Rodriguez,et al. Oligodendroglial tumors: diagnostic and molecular pathology. , 2010, Seminars in diagnostic pathology.
[73] D. Brat,et al. Newly Codified Glial Neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: Angiocentric Glioma, Pilomyxoid Astrocytoma and Pituicytoma , 2007, Brain pathology.
[74] D. Capper,et al. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology , 2011, Acta Neuropathologica.
[75] G. Reifenberger,et al. Distinct Expression Pattern of Microtubule‐Associated Protein‐2 in Human Oligodendrogliomas and Glial Precursor Cells , 2001, Journal of neuropathology and experimental neurology.
[76] Y. Piao,et al. Neuropathological Findings in Intractable Epilepsy: 435 Chinese Cases , 2010, Brain pathology.
[77] H. Urbach,et al. An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis , 2004, Acta Neuropathologica.
[78] Hendrik Witt,et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma , 2009, Acta Neuropathologica.
[79] J. Biegel,et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. , 2010, Neuro-oncology.
[80] G. Reifenberger,et al. Expression of the CD34 antigen in pleomorphic xanthoastrocytomas , 2003, Acta Neuropathologica.
[81] A. Palmini,et al. Developmental tumors and adjacent cortical dysplasia: Single or dual pathology? , 2013, Epilepsia.
[82] Christian Mawrin,et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.
[83] E. Perucca. Optimizing antiepileptic drug treatment in tumoral epilepsy , 2013, Epilepsia.
[84] C. Daumas-Duport,et al. Dysembryoplastic neuroepithelial tumors: Where are we now? , 2013, Epilepsia.
[85] B. Volk,et al. A clinicopathologic and immunomorphologic study of 13 cases of ganglioglioma , 1991, Cancer.
[86] Satoshi O. Suzuki,et al. MAP‐2e, a Novel MAP‐2 Isoform, Is Expressed in Gliomas and Delineates Tumor Architecture and Patterns of Infiltration , 2002, Journal of neuropathology and experimental neurology.
[87] R. Prayson. Brain tumors in adults with medically intractable epilepsy. , 2011, American journal of clinical pathology.
[88] P. Davies,et al. Novel microtubule‐associated protein‐2 isoform is expressed early in human oligodendrocyte maturation , 2000, Glia.
[89] Seung-Chyul Hong,et al. CD34 and microtubule‐associated protein 2 expression in dysembryoplastic neuroepithelial tumours with an emphasis on dual expression in non‐specific types , 2011, Histopathology.
[90] E R Laws,et al. Dysembryoplastic neuroepithelial tumor : a surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases , 1988 .
[91] C. Daumas-Duport,et al. Dysembryoplastic neuroepithelial tumors: Epileptogenicity related to histologic subtypes , 2013, Clinical Neurophysiology.
[92] E. Dazert,et al. mTOR signaling in disease. , 2011, Current opinion in cell biology.
[93] I. Blümcke,et al. Gangliogliomas: An Intriguing Tumor Entity Associated With Focal Epilepsies , 2002, Journal of neuropathology and experimental neurology.
[94] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.
[95] M. Rosenblum,et al. Monomorphous Angiocentric Glioma: A Distinctive Epileptogenic Neoplasm With Features of Infiltrating Astrocytoma and Ependymoma , 2005, Journal of neuropathology and experimental neurology.
[96] George Hadjivassiliou,et al. One Hundred and One Dysembryoplastic Neuroepithelial Tumors: An Adult Epilepsy Series With Immunohistochemical, Molecular Genetic, and Clinical Correlations and a Review of the Literature , 2011, Journal of neuropathology and experimental neurology.
[97] K. Aldape,et al. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. , 2012, Annals of diagnostic pathology.
[98] L. Dănăilă,et al. Angiocentric glioma: presentation of two cases with dissimilar histology. , 2008, Clinical neuropathology.
[99] D. Seidenwurm,et al. Angiocentric Neuroepithelial Tumor (ANET): A New Epilepsy‐Related Clinicopathological Entity with Distinctive MRI , 2005, Brain pathology.
[100] J. Uhm. IDH1 and IDH2 Mutations in Gliomas , 2009 .
[101] R. Fimmers,et al. Supratentorial gangliogliomas: Histopathologic grading and tumor recurrence in 184 patients with a median follow‐up of 8 years , 2004, Cancer.